ОЦЕНКА БИОЛОГИЧЕСКОГО ПОТЕНЦИАЛА ТРИТЕРПЕНОИДНЫХ САПОНИНОВ ASTRAGALUS МЕТОДОМ IN SILICO: PASS-СКРИНИНГ, ДЕСКРИПТОРНЫЙ АНАЛИЗ И SAR-ИНТЕРПРЕТАЦИЯ

Ашурова Х. ., Хаитбаев А. . & Rong Q. .


Annotatsiya

В статье выполнена сравнительная in silico оценка биологического потенциала astragaloside I-IV и cycloastragenol с использованием PASS Online. Дополнительно проведён дескрипторный анализ (MW, logP, TPSA, HBD, HBA) и SAR-интерпретация. Astragaloside II выделен как приоритетный кандидат по антитромботическому вектору, а astragaloside III и cycloastragenol - по гепатопротекторному направлению.


Adabiyotlar

  1. Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: prediction of activity spectra for biologically active substances. Bioinformatics. 2000;16(8):747-748. doi:10.1093/bioinformatics/16.8.747.
  2. Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskiy DS, Pogodin PV, et al. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Compd. 2014;50:444-457. doi:10.1007/s10593-014-1496-1.
  3. Geronikaki A, Lagunin A, Poroikov V, Filimonov D, et al. Computer aided prediction of biological activity spectra: evaluating versus known and predicting of new activities for thiazole derivatives. SAR QSAR Environ Res. 2002;13(3-4):457-471. doi:10.1080/10629360290014322.
  4. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2023: new data content and improved web interfaces. Nucleic Acids Res. 2023;51(D1):D1373-D1380. doi:10.1093/nar/gkac956.
  5. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi:10.1038/srep42717.
  6. Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform. 2009;1:8. doi:10.1186/1758-2946-1-8.
  7. Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014;28(9):1275-1283. doi:10.1002/ptr.5188. PMID:25087616.
  8. Ríos JL, Waterman PG. A review of the pharmacology and toxicology of saponins. J Ethnopharmacol. 1997;56(1):1-21. doi:10.1016/S0378-8741(97)00019-3.
  9. Liang Y, Li N, Tian M, et al. Pharmacological Effects of Astragaloside IV: A Review. Molecules. 2023;28(16):6118. doi:10.3390/molecules28166118.
  10. Yang C, Chen Y, Xu Y, et al. Review on the protective mechanism of astragaloside IV against neurological diseases. Front Pharmacol. 2023;14:1187910. doi:10.3389/fphar.2023.1187910.
  11. Gu Y, Wang G, Pan G, Fawcett JP, A J, Sun J. Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali. Basic Clin Pharmacol Toxicol. 2004;95(6):295-298. doi:10.1111/j.1742-7843.2004.t01-1-pto950508.x. PMID:15569275.
  12. Zhou RN, Song YL, Ruan JQ, Wang YT, Yan R. Pharmacokinetic evidence on the contribution of intestinal bacterial conversion to beneficial effects of astragaloside IV, a marker compound of astragali radix, in traditional oral use of the herb. Drug Metab Pharmacokinet. 2012;27(6):586-597. doi:10.2133/dmpk.dmpk-11-rg-160. PMID:22673033.
  13. Huang CR, Wang GJ, Wu XL, et al. Absorption enhancement study of astragaloside IV based on its transport characteristics in Caco-2 cell monolayers. Eur J Pharm Sci. 2006;29(3-4):229-236. PMID:16715776.
  14. Ip FCF, Ng YP, An HJ, Dai Y, Pang HH, Hu YQ, et al. Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management. Neurosignals. 2014;22(1):52-63. doi:10.1159/000365290. PMID:25095809.
  15. Valenzuela HF, Fuller T, Edwards J, Finger D, Molgora B. Cycloastragenol extends T cell proliferation by increasing telomerase activity. J Immunol. 2009;182(Suppl 1):90.30. doi:10.4049/jimmunol.182.Supp.90.30.
  16. Zhu J, et al. In vitro intestinal absorption and first-pass intestinal and hepatic metabolism of cycloastragenol, a potent small molecule telomerase activator. Drug Metab Pharmacokinet. 2010;25(5):477-486.
  17. Wang P, Wang Z, Zhang Z, Cao H, Kong L, Ma W, Ren W. Astragalus membranaceus: botany, phytochemistry, traditional uses, pharmacology, toxicology, and quality control. Front Pharmacol. 2023;14:1242318. doi:10.3389/fphar.2023.1242318.
  18. Bratkov VM, Shkondrov AM, Zdraveva PK, Krasteva IN. Flavonoids from the genus Astragalus: phytochemistry and biological activity. Pharmacogn Rev. 2016;10(19):11-32. doi:10.4103/0973-7847.176550.
  19. Idrees M, [соавт.]. Cycloastragenol activation of telomerase improves β-Klotho gene expression in an aging model. Preprint; Year. Europe PMC ID: 36462538.
  20. Stępnik K, et al. In Vivo Insights into the Role of Astragaloside IV in Metabolic and Inflammatory Disorders. Int J Mol Sci. 2025;26(9):4250. doi:10.3390/ijms26094250.
  21. Landrum G. RDKit: Open-source cheminformatics. (Software, version used: 2024.09.6).
  22. Sigma-Aldrich. Astragaloside I (PHL89572): SMILES/InChIKey data sheet. Accessed 18 Feb 2026.
  23. Sigma-Aldrich. Astragaloside II (SML1643): SMILES/InChIKey data sheet. Accessed 18 Feb 2026.
  24. Sigma-Aldrich. Astragaloside IV (SML0437): SMILES/InChIKey data sheet. Accessed 18 Feb 2026.
  25. Sigma-Aldrich. Cycloastragenol (SML1448): SMILES/InChIKey data sheet. Accessed 18 Feb 2026.